Concepedia

Hideko Isozaki

HI

15

Publications

971

Citations

12

H-Index

1999

Active since

Affiliations

Okayama University Hospital(Current)

Okayama University

Kawasaki Medical School

Massachusetts General Hospital

Harvard University

Hideko Isozaki is an author at Okayama University Hospital specializing in medicine, oncology, and tumor biology.

Top concepts

MedicineOncologyCell BiologyTumor BiologyCancer BiologyLung CancerCancer ResearchRadiation OncologyCancer Cell BiologyPharmacology

Publications per year

1999–2023

15

Publications

15

Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion

Zofia Piotrowska, Hideko Isozaki, Jochen K. Lennerz et al. · Cancer Discovery · 2018 · 434 citations

Therapy-induced APOBEC3A drives evolution of persistent cancer cells

Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi et al. · Nature · 2023 · 130 citations · Full text

Tumor Biology, Medicine, Tumor Suppressor +4

Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases

Hideko Isozaki, Eiki Ichihara, Nagio Takigawa et al. · Cancer Research · 2016 · 128 citations · Full text

Oncology, Medicine, Receptor Tyrosine Kinase +15

Genetic alterations of candidate tumor suppressor ING1 in human esophageal squamous cell cancer.

L. Chen, N. Matsubara, Teruo Yoshino et al. · PubMed · 2001 · 79 citations

Tumor Biology, Squamous Cell Cancer, Esophageal Cancer +14

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC

Naoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto et al. · Journal of Thoracic Oncology · 2023 · 37 citations · Full text

Rows per page

1–5 of 15